Physician profile

Gary A Croll

Internal Medicine · Dallas, TX

NPI 1962445916

$1,492.07

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $232.79 2019-2022
Glaxosmithkline, LLC. $205.01 2019-2022
Amgen INC. $126.11 2019-2021
Pfizer INC. $121.57 2019-2022
Novartis Pharmaceuticals Corporation $93.73 2019-2021
Abbott Laboratories $87.25 2021-2022
Astrazeneca Pharmaceuticals Lp $79.32 2020-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $76.80 2019-2022
Lilly USA, LLC $72.82 2021-2022
Amarin Pharma, INC. $69.52 2019-2022
Abbvie INC. $62.41 2021-2022
Covis Pharma Gmbh $47.44 2021
Astellas Pharma US INC $46.47 2020-2021
Boston Scientific Corporation $39.94 2019
Merck Sharp & Dohme LLC $37.09 2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Biogen, INC. $20.94 2021
Assertio Therapeutics, INC. $16.31 2020
Dexcom, INC. $16.01 2022
Scilex Pharmaceuticals INC. $15.40 2019
E.R. Squibb & Sons, L.L.C. $13.19 2021
Melinta Therapeutics, LLC $11.95 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary A Croll

$1,492.07

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/315464/gary-a-croll

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.